KKKarineh Kazazian

Karineh Kazazian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karineh Kazazian has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Transcriptomic profiling of a novel gastric implantation model identifies mechanisms and pathways that drive implantation into explanted human peritoneum

    by Deanna Ng, Karineh Kazazian, Kiera Lee, Yi Qing Lu, Aiman Ali, Karina Pacholczyk, Savtaj Brar, James Conner, Igor Jurisica, Christopher Allan McCulloch, et al.

  • Transcriptomic profiling of a novel gastric implantation model identifies mechanisms and pathways that drive implantation into explanted human peritoneum

    by Deanna Ng, Karineh Kazazian, Kiera Lee, Yi Qing Lu, Aiman Ali, Karina Pacholczyk, Savtaj Brar, James Conner, Igor Jurisica, Christopher Allan McCulloch, et al.

    Epithelial cancers such as stomach and ovarian cancer tend to metastasize to the peritoneum, often leading to intractable disease and poor survival. The mechanisms that enable gastric cancer cells to implant, invade, and survive in the peritoneal niche are poorly understood. We developed a novel human peritoneal explant model using freshly harvested peritoneal tissue samples. GFP-labeled human gastric adenocarcinoma cells (AGS) were co-cultured with the peritoneal samples, and 2% of these cells implanted into the peritoneum. The transcriptomic profile of the implanted AGS cells was compared to AGS cells that failed to implant using RNA sequencing. Differentially expressed genes in implanted AGS cells were enriched for cell adhesion and motility. We functionally validated these genes with CRISPR knockout and identified ADAM12 as a regulator of peritoneal metastasis. ADAM12 KO significantly impaired peritoneal metastasis in vivo and ex vivo and marked disruption of the ITGβ1 interactome in GCa cells. Our approach and the new data identify a distinct peritoneal metastasis gene set that facilitates the implantation and invasion of gastric cancer cells within the peritoneum. Disruption of these pathways with peritoneal-directed therapies has the potential to improve survival in patients with high-risk primary gastric cancer.

  • Open Access

    A Consensus Approach to the Incorporation of Total Neoadjuvant Therapy in a Treatment Algorithm for Stage I–III Resectable Rectal Cancer

    by Sami A. Chadi, Karineh Kazazian, Paul Savage, Christine Brezden-Masley, Ron Burkes, Eric Chen, Anand Govindarajan, Ali Hosni, Raymond Jang, Erin Kennedy, et al.

    Advances in surgical techniques, radiographic imaging capabilities, radiotherapy, and chemotherapy have led to improved outcomes for patients with rectal adenocarcinoma. Treatment strategies have correspondingly evolved, as seen with total neoadjuvant therapy (TNT) and organ preservation approaches. TNT is a treatment strategy for primary, non-metastatic, resectable mismatch repair proficient rectal cancer where the intent is to administer all appropriate adjuvant therapy in the preoperative phase, including both systemic therapy and chemoradiotherapy/radiotherapy. In this setting, TNT is increasingly administered for the purposes of maximizing tumour response to facilitate resection, improving treatment compliance, thus increasing the likelihood of a complete response to allow for organ preservation and for the possibility of improving survival. While several recent randomized controlled trials have described the role of TNT in the contemporary treatment of rectal cancer, there is significant heterogeneity in sequencing of treatments, dosing, allowance for non-operative management, and the potential for over-treatment. Our objective here was to incorporate current evidence to develop a consensus-based institutional treatment algorithm to be used in the ambulatory and multidisciplinary team setting for the treatment of stage I–III rectal cancer.

  • Open Access

    Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium

    by Kirsten M. Farncombe, Julia A. Sobotka, Melyssa Aronson, Mark Basik, Yvonne Bombard, Leslie Born, Rona Cheifetz, Marc Clausen, Natalie Coburn, Lesa Dawson, et al.

    Individuals with hereditary cancer syndromes are born with germline genetic variants that significantly increase their lifetime risk of developing multiple cancers. Cancer rates and overall mortality can be reduced with intensive surveillance to facilitate early cancer detection. However, participating in diagnostic imaging and endoscopy surveillance programs is often time-consuming, overwhelming, inconvenient, and anxiety-inducing. To improve this, multi-cancer early detection tests are being developed using cell-free DNA (cfDNA) sequencing analysis to detect cancers with more sensitivity than conventional screening methods. Our community (the CHARM consortium: Cell-free DNA in Hereditary And high-Risk Malignancies) has been exploring the use of cfDNA sequencing in hereditary cancer, and has launched the CHARM2 prospective randomized controlled trial, which is enrolling 1000 participants with Hereditary Breast and Ovarian Cancer, Lynch syndrome, Li-Fraumeni syndrome, Neurofibromatosis type 1 and Hereditary Diffuse Gastric Cancer to improve equitable access, early detection and surveillance for high-risk individuals. All participants will have screening as per conventional syndrome-specific surveillance recommendations. Half the participants (experimental cohort) will also have cfDNA analysis at least three times a year, with abnormal results triggering dedicated clinical imaging and diagnostic evaluation, and heightened surveillance. Vetted by our patient advisors, validated patient-reported outcome and experience measures assessing participant psychosocial outcomes, engagement, and test preferences will be administered to both arms. Our goal is to inform if and how cfDNA analysis could be implemented into routine clinical care and offer a path to equitable and more convenient cancer screening for all high-risk Canadians.


  • Open Access

    Transcriptomic profiling of a novel gastric implantation model identifies mechanisms and pathways that drive implantation into explanted human peritoneum

    by Deanna Ng, Karineh Kazazian, Kiera Lee, Yi Qing Lu, Aiman Ali, Karina Pacholczyk, Savtaj Brar, James Conner, Igor Jurisca, Christopher Allan McCulloch, et al.

    Epithelial cancers such as stomach and ovary cancer tend to metastasize to the peritoneum, often leading to intractable disease and poor survival. Currently, the mechanisms that enable gastric cancer cells to penetrate the mesothelium, and to implant, invade, and survive in the peritoneal niche are poorly understood. To investigate these mechanisms, we developed a novel human peritoneal explant model. Briefly, fresh peritoneal tissue samples from abdominal surgery patients were cultured on top of a layer of GFP-labeled human gastric adenocarcinoma cells (AGS); 2% of these cells implanted into the peritoneum. The transcriptomic profile of the implanted AGS cells was compared to the profile of AGS cells that failed to implant using RNA sequencing. Differentially expressed genes were enriched significantly (fold change>2) for genes that enable cell adhesion, motility, and membrane depolarization. We compared this list of genes with a previously identified peritoneal metastasis whole exome sequencing dataset (SRP043661). Upon further analysis based on subcellular localization, cell adhesion and cytoskeletal organization, we found nine core “peritoneal implantation” genes. We functionally validated these genes with CRISPR knockout and assessed peritoneal implantation and invasion using the human peritoneal explant model described above. From these data we identified ADAM12 as a key player of peritoneal metastasis. Knock out of ADAM12 significantly impaired peritoneal metastasis in vivo and ex vivo . Exploration of three publicly available independent datasets indicated that ADAM12 is indeed clinically relevant in peritoneal metastasis. To explore the role of ITGAβ1 in mediating cell-matrix interactions in the presence of ADAM12, we performed ITGAβ1 pull-down assays followed by mass spectrometry analysis in ADAM12 WT cells. ADAM12 KO cells show a marked disruption of the ITGAβ1 interactome in GCa cells. Key cytoskeletal proteins such as MYH14, MYH10, MYH9, ACTA2, SPTN1 and TPM1–TPM4 were found to be interactors with ITGAβ1 in ADAM12 WT cells but not ADAM12 KO cells. Our approach and the new data identify a distinct peritoneal metastasis gene set that facilitates implantation and invasion of gastric cancer cells within the peritoneum. Disruption of these pathways with peritoneal-directed therapies has the potential to improve survival in patients with high-risk primary gastric cancer.